Your AI-Trained Oncology Knowledge Connection!
Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.
Patients with low-risk meningioma had a 3-year progression-free survival that modestly exceeded expectations after gross total resection followed by observation.
Patients with endometrial and cervical cancer reported significantly less acute gastrointestinal toxicity when treated with pelvic intensity-modulated radiation therapy as opposed to standard pelvic radiation therapy.
Chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival compared with involved-field radiotherapy alone.
David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.
Erin Murphy, MD, associate staff, Department of Radiation Oncology, Cleveland Clinic, discusses a study examining prognostic factors of patients with glioma.
Karyn A. Goodman, MD, radiation oncologist, professor in the Department of Radiation Oncology, University of Colorado Denver, discusses ongoing trials in the field of radiation oncology.
Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.
Robert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses the analysis of the Pooled Registry of Multicatheter Interstitial Sites Experience, which examined the safety of accelerated partial breast irradiation via multicatheter interstitial brachytherapy.
Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, discusses a European study that examined the efficacy of accelerated partial breast irradiation versus conventional whole breast irradiation in patients with low-risk breast cancer.
The oral corticosteroid dexamethasone significantly decreased flares of bone pain when added to radiation therapy in patients with metastatic cancer.
Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.
The additon of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial.
Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.
Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer and brain metastases.
The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.
Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.
Dwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.
Gustavo Olivera, PhD, from 21st Century Oncology, discusses an analysis of a radiation oncology registry.
Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.
Daniel H. Galmarini, Chief Technology Officer/Director, Physics and Engineering, 21st Century Oncology, provides an overview of adaptive radiotherapy.
High pretreatment levels of serum VEGF-A and TGF-β1 indicated significantly worse disease-free survival (DFS) following neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Timing of metastatic development, lymph node involvement, and type of disease all factor into the overall survival rate of patients with stage IV NSCLC.
The combination of chemotherapy and stereotactic ablative radiotherapy (SABR) may allow patients with locally advanced pancreatic cancer to undergo surgery, a procedure that might not have otherwise been an option
With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option
When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)-as opposed to a 36-month course-not only generates similar long-term outcomes, but results in a better quality of life
Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer
Despite a recent decline in utilization, consolidated radiation therapy has been shown to improve 10-year survival rates for patients with stage I/II Hodgkin's lymphoma following treatment with chemotherapy
